spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Northway Biotechpharma


History of Rapid Growth
Founded in 2004 as a CDMO providing support for branded biologics and biosimilars, Northway Biotechpharma –– then just Biotechpharma –– began operating in rented space for product development and small-scale GMP manufacturing activities. During the past 15 years, the company has become a full-service CDMO with capabilities in cell line development, process development and optimization and mid-volume GMP manufacturing of biologic drug substances and drug products –– both branded biopharmaceuticals and biosimilars.

Strong Customer Focus
Throughout its first 15 years, Northway Biotechpharma has focused on providing its customers with the highest level of quality and service. Today, the track record of performance and high level of trust that the CDMO has established with its customers result in frequent recommendations and an increasing number of customers. Northway Biotechpharma is deeply invested in providing high quality, world-class CDMO services and long-term partnerships based on its blend of experience and openly collaborative project teams.

Ongoing Commitment to Reinvestment
The commitment to Northway Biotechpharma’s customers is also reflected in the company’s ongoing willingness to reinvest and enhance its services and capabilities. Recent management changes, new branding and new capacity are enabling Northway Biotechpharma to further advance its mission of becoming a single-source CDMO able to support its worldwide customers with a full range of development and manufacturing services from the clinic to the market.

Exciting Future Ahead
“The entire history of Northway Biotechpharma is important and has made an impact on what we are today and helped establish the values we live by: leadership, openness to change, creativity, strategic discipline and excellent execution are the keys to our success,” commented Dr. Vladas Bumelis, founder of Biotechpharma and Chairman of the company’s Board of Directors and Advisory Board.

Giedrius Žunda, CEO of Northway Biotechpharma, added “I see a great opportunity to leverage the company’s vertically integrated business model and to lead its talented employees to deliver increased value for shareholders. I am excited to lead this organization to its next stage of evolution.” About Northway Biotechpharma Northway Biotechpharma is a contract development and manufacturing organization (CDMO) supporting worldwide customers. Its highly experienced biochemistry, biology and bioprocess engineering staff can deliver projects at any stage, from cell line construction and process development to cGMP production of biopharmaceutical products. High-quality performance and on-time delivery are guaranteed by a team of highly qualified and experienced researchers, engineers, technologists and management professionals.
email bd@northwaybiotech.com
web https://www.northwaybiotech.com/
email Northway Biotechpharma Mokslininku str. 4 LT-08412 Vilnius, Lithuania
 
Print this page
Send to a friend
   
spacer
News and Press Releases

IATA CEIV Pharma certificate of Turkish Cargo renewed

Turkish Cargo, the air cargo brand flying to the most countries around the world, extended the validity period of its IATA CEIV (Center of Excellence for Independent Validators) Pharma certificate to 2022, proving its success in all processes throughout the air transportation of medicinal products.
More info >>


White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement